Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 800 results for "Ibrutinib"

[News] Ibrutinib in pretreated Waldenström's macroglobulinaemia

New research suggests that ibrutinib—an inhibitor of Bruton's tyrosine kinase—has substantial activity and is safe for use in previously treated patients with Lancet Neurology, 2 days ago

Human medicines European public assessment report (EPAR): Imbruvica, ibrutinib, Revision: 1, Authorised

This is a summary of the European public assessment report (EPAR) for Imbruvica. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 week ago

Ibrutinib (IMBRUVICA®) Improves Outcomes for Pancreatic Ductal Adenocarcinoma in Mouse Models

/PRNewswire/ --Ibrutinib (IMBRUVICA ® ) data presented yesterday by Pharmacyclics, Inc. (NASDAQ: PCYC) at the American Association for Cancer Research (AACR) Annual Meeting suggest that ibrutinib may be an effective therapeutic option for ...
 ADVFN India1 week ago Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma  News-Medical.Net1 week ago IMBRUVICA(R) (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, in Patients with Chronic Lymphocytic Leukemia (CLL)  Scottrade1 week ago IMBRUVICA longer-term follow-up data demonstrate durable responses, including complete responses, in patients with chronic lymphocytic leukemia  Medical News Today1 week ago

'New Era' in the Treatment of Rare Lymphoma

New data on ibrutinib ( Imbruvica , Pharmacyclics and Janssen), which recently became the first drug approved for Waldenström's macroglobulinemia, show that the agent provides ongoing control of the rare lymphoma. In a prospective phase2 ...
 General Medicine eJournal3 weeks ago Ibrutinib  CancerConnect.com1 month ago
Digital Journal

AbbVie to acquire Pharmacyclics

AbbVie, Inc. has signed a definitive agreement to acquire Pharmacyclics, Inc. and its flagship asset Imbruvica(R) (ibrutinib), a treatment for hematologic malignancies, for approximately $21,000 million. AbbVie and Pharmacyclics are US-based ...
 Individual.com1 month ago AbbVie to buy Pharmacyclics for $21 bn, to create an industry leading hematological oncology franchise  PharmaBiz1 month ago AbbVie Acquires Oncology Drug Firm Pharmacyclics for $21B  Genetic Engineering News1 month ago AbbVie to acquire Pharmacyclics for $21B, boosting hematological oncology franchise  Center Watch1 month ago

It's A Drug! It's A Pipeline! It's A New Blockbuster Model!

When AbbVie's CEO Rick Gonzalez described his recently acquired product ibrutinib (Imbruvica) as offering a pipeline in a drug, I imagine every business development executive in biopharma chuckled. No question each of them has used this exact line ...
 Forbes.com1 month ago
Science Daily

New Waldenstrom's drug shows sustained benefit at two years

( Dana-Farber Cancer Institute ) Dana-Farber researchers report in the New England Journal of Medicine that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continues to control the rare blood cancer, with 95 percent of patients ...
 Infrosoft3 weeks ago New Waldenström's drug shows sustained benefit at two years  OncologyNurse.com3 weeks ago Newly approved drug for rare blood cancer shows sustained benefit for 2 years  News-Medical.Net3 weeks ago Newly approved drug for Waldenstrom's Macroglobulinemia shows sustained benefit for 2 years  News-Medical.Net3 weeks ago

Phase 3 Study with IMBRUVICA® (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression

/PRNewswire/ --Janssen Research & Development, LLC (Janssen) announced today that a pre-planned interim analysis of the Phase 3 HELIOS (CLL3001) study investigating the combination of IMBRUVICA ® (ibrutinib) plus bendamustine and rituximab (BR) ...
 RCL Advisors1 month ago Phase 3 Study with IMBRUVICA (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression  FirstWord Pharma1 month ago Phase 3 Study with IMBRUVICA?? (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression  Tutorial Finder1 month ago Phase 3 Study with IMBRUVICA(r) (ibrutinib) Combination Demonstrates  Finwin1 month ago
Catholic Online

New drug may actually stave off chemotherapy

Miracle drug Ibrutinib could spare blood cancer patients painful chemotherapy Ibrutinib, hailed as a revolutionary drug capable of "switching off" cancer may soon be offered to patients with some forms of the disease. The once-a-day tablet ...
 Catholic Online1 month ago Doctors hail drug that can 'turn off cancer': Once-a-day tablet could spare blood cancer patients effects of traditional chemotherapy  Capital Bay1 month ago US accredited non-chemical drug eliminates blood cancer by 95%  Egypt Independent3 weeks ago Amgen's colorectal cancer drug EU approved  Pharmafocus3 weeks ago

Poor outcomes likely for ibrutinib-resistant patients with mantle cell lymphoma

Patients with mantle cell lymphoma who experience progression after ibrutinib treatment likely will not respond to salvage chemotherapy, according to results of a retrospective review. Ibrutinib (Imbruvica; Pharmacyclics, Janssen), an oral ...
 Orthopedics Today1 month ago Ibrutinib discontinuation linked to poor prognosis in CLL  Orthopedics Today1 month ago Reasons for ibrutinib therapy discontinuation in CLL  FirstWord Pharma2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Ibrutinib
Get updated on latest news & your favorite topics right in your inbox!
More     Less